Tetracycline Salt Polymorphs for Stable Bioavailable Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tetracycline compounds face issues with stability and bioavailability due to polymorphic forms, leading to potential overdosing and regulatory challenges, necessitating the development of stable crystalline forms and salts with optimal physical and chemical properties.
Innovation Solution
Development of stable crystalline forms and salts, such as the tosylate, HCl, and mesylate salts of Compound 1, along with their polymorphs, which exhibit improved stability and bioavailability, characterized by specific X-ray diffraction peaks and temperature stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tetracycline compounds are used in therapeutic applications, then antimicrobial effectiveness is improved, but stability and bioavailability issues arise due to polymorphic forms
Solution Approach 1:
The patent applies parameter changes by converting the tetracycline compound into different salt forms (tosylate, HCl, mesylate salts) and identifying specific polymorphic forms (Forms I, II, III) with distinct crystal structures. Each salt form and polymorph exhibits different physical and chemical parameters including solubility, stability, and bioavailability, allowing optimization of therapeutic properties while maintaining antimicrobial effectiveness
Solution Approach 2:
The patent creates composite material structures by forming specific crystalline polymorphic forms of tetracycline salts. These composite structures with defined molecular arrangements in the crystal lattice provide enhanced stability and controlled bioavailability, resolving the contradiction between effectiveness and stability through structured material design
2Quantity of substance
If multiple polymorphic forms exist, then bioavailability varies, but this leads to potential overdosing and regulatory challenges
Solution Approach 1:
The patent systematically characterizes different polymorphic forms (I, II, III) and salt forms with distinct physical parameters including melting points, solubility, and dissolution rates. By establishing these parameter differences, the patent enables selection of specific forms with predictable bioavailability, preventing overdosing through controlled parameter optimization
Solution Approach 2:
The patent replaces empirical dosage determination with systematic characterization of crystal structures using X-ray diffraction patterns and other analytical methods. This substitution of mechanical/empirical approaches with analytical characterization enables precise control of bioavailability and safety margins
3Stability of the object's composition
If stable crystalline forms are developed, then stability and bioavailability are improved, but characterization and manufacturing complexity increase
Solution Approach 1:
The patent uses distinctive X-ray diffraction patterns as fingerprint characteristics for each polymorphic form (I, II, III) and salt form. These unique diffraction patterns serve as simple, reproducible identification markers that simplify characterization and quality control, offsetting the complexity of developing stable crystalline forms
Solution Approach 2:
The patent establishes specific physical parameters (melting points, solubility values, density) for each stable crystalline form and salt form. By defining these parameters, the patent creates clear specification criteria that simplify manufacturing control and quality assurance, reducing the practical complexity despite the scientific complexity of characterizing multiple forms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable crystalline forms and salts of Compound 1 provide enhanced stability, solubility, and bioavailability, addressing regulatory concerns and ensuring safe and effective therapeutic dosages.
Implementation Method 1
characterized by specific X-ray diffraction peaks
Data Source
AI summary
Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.